TTM
84.5%
YoY change
−0.77pp
Trough year (1991)
-75.3%
Peak year (2009)
95.8%
Latest annual
85.4%
Gross Margin history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: 85.4%
Gross Margin change chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Latest: −0.77pp
Gross Margin history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| 2025 | 85.4% | -0.77pp | ||
| 2024 | 86.1% | +3.24pp | ||
| 2023 | 82.9% | -3.10pp | ||
| 2022 | 86.0% | +2.94pp | ||
| 2021 | 83.1% | -0.99pp | ||
| 2020 | 84.0% | -1.08pp | ||
| 2019 | 85.1% | -6.20pp | ||
| 2018 | 91.3% | +0.56pp | ||
| 2017 | 90.8% | -0.92pp | ||
| 2016 | 91.7% | +3.07pp | ||
| 2015 | 88.6% | -2.26pp | ||
| 2014 | 90.9% | +0.20pp | ||
| 2013 | 90.7% | -0.53pp | ||
| 2012 | 91.2% | -0.89pp | ||
| 2011 | 92.1% | -3.17pp | ||
| 2010 | 95.3% | -0.54pp | ||
| 2009 | 95.8% | +0.92pp | ||
| 2008 | 94.9% | — | ||
| 2006 | 64.2% | +2.02pp | ||
| 2005 | 62.1% | +49.09pp | ||
| 2004 | 13.0% | -75.34pp | ||
| 2003 | 88.4% | +17.87pp | ||
| 2002 | 70.5% | +0.14pp | ||
| 2001 | 70.4% | -3.36pp | ||
| 2000 | 73.7% | -15.83pp | ||
| 1999 | 89.6% | +2.65pp | ||
| 1998 | 86.9% | -5.23pp | ||
| 1997 | 92.1% | -3.29pp | ||
| 1996 | 95.4% | — | ||
| 1991 | -75.3% | -49.34pp | ||
| 1990 | -26.0% | — |
- 202585.4%-0.77pp
- 202486.1%+3.24pp
- 202382.9%-3.10pp
- 202286.0%+2.94pp
- 202183.1%-0.99pp
- 202084.0%-1.08pp
- 201985.1%-6.20pp
- 201891.3%+0.56pp
- 201790.8%-0.92pp
- 201691.7%+3.07pp
- 201588.6%-2.26pp
- 201490.9%+0.20pp
- 201390.7%-0.53pp
- 201291.2%-0.89pp
- 201192.1%-3.17pp
- 201095.3%-0.54pp
- 200995.8%+0.92pp
- 200894.9%—
- 200664.2%+2.02pp
- 200562.1%+49.09pp
- 200413.0%-75.34pp
- 200388.4%+17.87pp
- 200270.5%+0.14pp
- 200170.4%-3.36pp
- 200073.7%-15.83pp
- 199989.6%+2.65pp
- 199886.9%-5.23pp
- 199792.1%-3.29pp
- 199695.4%—
- 1991-75.3%-49.34pp
- 1990-26.0%—
Gross Margin values are taken from Regeneron Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Margin at Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported gross margin is 84.5%. Gross margin is gross profit divided by revenue, expressed as a percentage. It shows how much of each sales dollar survives the direct cost of goods sold — before operating expenses, interest, and taxes. A higher gross margin generally signals pricing power and production efficiency. Margins are most meaningful compared against sector peers and a company's own history.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported gross margin of 85.35% – contracted 0.8 percentage points year-over-year.
The record annual gross margin stands at 95.80%, reached in 2009; the historical low of -75.34% was recorded in 1991.
Regeneron Pharmaceuticals Gross Margin by Year
Regeneron Pharmaceuticals Gross Margin 2025: 85.4%
In 2025, Regeneron Pharmaceuticals reported gross margin of 85.35%, contracted 0.8 percentage points from 2024.
Regeneron Pharmaceuticals Gross Margin 2024: 86.1%
Regeneron Pharmaceuticals gross margin in 2024 was 86.13%, expanded 3.2 percentage points from 2023.
Regeneron Pharmaceuticals Gross Margin 2023: 82.9%
2023's gross margin for Regeneron Pharmaceuticals came in at 82.89%, contracted 3.1 percentage points from 2022.
Regeneron Pharmaceuticals Gross Margin 2022: 86.0%
Regeneron Pharmaceuticals posted gross margin of 85.99% in 2022, expanded 2.9 percentage points from 2021.
Regeneron Pharmaceuticals Gross Margin 2021: 83.1%
Regeneron Pharmaceuticals gross margin in 2021 was 83.05%.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers by Gross Margin
Healthcare peers of Regeneron Pharmaceuticals (REGN), ranked by their latest gross margin
| 83.5% | |
| 81.8% | |
| 81.7% | |
| 75.9% | |
| 71.5% | |
| 70.7% | |
| 70.0% | |
| 18.8% |
- 83.5%
- 81.8%
- 81.7%
- 75.9%
- 71.5%
- 70.7%
Frequently asked questions
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation